A citation-based method for searching scientific literature

John Dupré, Margaret T Behme, Thomas J McDonald. J Clin Endocrinol Metab 2004
Times Cited: 92







List of shared articles



Times cited

Exendin-4 increases the expression of hypoxia-inducible factor-1α in rat islets and preserves the endocrine cell volume of both free and macroencapsulated islet grafts.
Xiaohui Jia, Amit Sharma, Makiko Kumagai-Braesch, Annika M Wernerson, Anne K Sörenby, Shinji Yamamoto, Feng Wang, Annika B Tibell. Cell Transplant 2012
12

Insulin deficiency, but not resistance, exaggerates cognitive deficits in transgenic mice expressing human amyloid and tau proteins. Reversal by Exendin-4 treatment.
Matthew R King, Nicholas J Anderson, Mihaela Deciu, Lucie S Guernsey, Morgan Cundiff, Shohreh Hajizadeh, Corinne G Jolivalt. J Neurosci Res 2020
3


Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.
Nasib Ervinna, Tomoya Mita, Eisuke Yasunari, Kosuke Azuma, Rica Tanaka, Satoshi Fujimura, Dewi Sukmawati, Takashi Nomiyama, Akio Kanazawa, Ryuzo Kawamori,[...]. Endocrinology 2013
122

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95

β-Cell differentiation and regeneration in type 1 diabetes.
L Ding, C Gysemans, C Mathieu. Diabetes Obes Metab 2013
18

The Impacts of Gastroileostomy Rat Model on Glucagon-like Peptide-1: a Promising Model to Control Type 2 Diabetes Mellitus.
Behrouz Keleidari, Rastin Mohammadi Mofrad, Shahab Shahabi Shahmiri, Mohammad Hossein Sanei, Mohsen Kolahdouzan, Erfan Sheikhbahaei. Obes Surg 2018
1

Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver.
Dan Zheng, Viorica Ionut, Vahe Mooradian, Darko Stefanovski, Richard N Bergman. Diabetes 2009
31

Glycaemic control in type 2 diabetes: targets and new therapies.
Abd A Tahrani, Milan K Piya, Amy Kennedy, Anthony H Barnett. Pharmacol Ther 2010
104

The GLP-1 system as a therapeutic target.
C Mark B Edwards. Ann Med 2005
12

Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
Urd Kielgast, Jens J Holst, Sten Madsbad. Curr Diabetes Rev 2009
37

GLP-1: physiological effects and potential therapeutic applications.
Kasper Aaboe, Thure Krarup, Sten Madsbad, Jens Juul Holst. Diabetes Obes Metab 2008
57



The role of beta-cell dysfunction in early type 1 diabetes.
Emily K Sims, Raghavendra G Mirmira, Carmella Evans-Molina. Curr Opin Endocrinol Diabetes Obes 2020
8

Glucagon-like peptide 1 and type 1 diabetes: NOD ready for prime time?
Irene Hadjiyanni, Daniel J Drucker. Endocrinology 2007
6

New potential adjuncts to treatment of children with type 1 diabetes mellitus.
Vandana S Raman, Rubina A Heptulla. Pediatr Res 2009
13

The latest pharmacotherapy options for type 1 diabetes.
Johnny Ludvigsson. Expert Opin Pharmacother 2014
11


Is exenatide a useful addition to diabetes therapy?
Nasser E Mikhail. Endocr Pract 2006
4

Exenatide: incretin therapy for patients with Type 2 diabetes mellitus.
Abd A Tahrani, Milan K Piya, Anthony H Barnett. Expert Rev Endocrinol Metab 2008
2

Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes.
A Sharma, A Sörenby, A Wernerson, S Efendic, M Kumagai-Braesch, A Tibell. Diabetologia 2006
33


Glucagon and glucagon-like peptide receptors as drug targets.
J L Estall, D J Drucker. Curr Pharm Des 2006
67

Exenatide.
Anthony H Barnett. Drugs Today (Barc) 2005
19